Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 28Genitourinary 13Breast 12Thoracic 8Other solid neoplasm 8Dermatologic 5Sarcoma 4Plasma cell 4Other hematologic neoplasm 4Tumor-Agnostic 3Gynecologic 3CNS 3Myeloid 2Lymphoid 2Other 1Head & Neck 1

Conditions

Melanoma 5Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Hydroxychloroquine × Dermatologic × Clear all
NCT04464759 2026-05-11

LIMIT

Abramson Cancer Center at Penn Medicine

Phase 1/2 Recruiting
94 enrolled
Dermatologic

Melanoma

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT00962845 2022-09-07

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Completed
20 enrolled
Dermatologic

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown
63 enrolled
Dermatologic

Melanoma

NCT01897116 2020-05-29

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡